Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (66.7%)
Phase 31 (33.3%)

Trials by Status

completed133%
recruiting267%

Recent Activity

2 active trials
Showing 3 of 3
completedphase_3

A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

NCT06671392
recruitingphase_1

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions

NCT07260851
recruitingphase_1

Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.

NCT07267221

Clinical Trials (3)

Showing 3 of 3 trials
NCT06671392Phase 3

A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

Completed
NCT07260851Phase 1

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions

Recruiting
NCT07267221Phase 1

Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3